Giulia Malaguarnera

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8931124/publications.pdf

Version: 2024-02-01

94 papers 4,347 citations

38 h-index 63 g-index

95 all docs 95 docs citations 95 times ranked 6172 citing authors

#	Article	IF	CITATIONS
1	Serum Folate deficiency in HCV related Hepatocellular Carcinoma. Scientific Reports, 2022, 12, 5025.	3.3	3
2	Hepatitis C Virus Infection Increases Fatigue in Health Care Workers. Diseases (Basel, Switzerland), 2020, 8, 37.	2.5	2
3	High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer. Biomedicines, 2020, 8, 265.	3.2	3
4	Carnitine Serum Levels in Frail Older Subjects. Nutrients, 2020, 12, 3887.	4.1	10
5	Folate levels in hepatocellular carcinoma patients with portal vein thrombosis. BMC Gastroenterology, 2020, 20, 375.	2.0	O
6	Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients, 2020, 12, 1389.	4.1	52
7	Dry Eye in Systemic Sclerosis Patients: Novel Methods to Monitor Disease Activity. Diagnostics, 2020, 10, 404.	2.6	5
8	Decrease in Serum Vitamin D Level of Older Patients with Fatigue. Nutrients, 2019, 11, 2531.	4.1	24
9	Vitamin D Serum Levels in Patients with Statin-Induced Musculoskeletal Pain. Disease Markers, 2019, 2019, 1-6.	1.3	26
10	Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis. Current Molecular Medicine, 2019, 19, 532-538.	1.3	4
11	latrogenic nerve lesion following laparoscopic surgery. A case report. Annals of Medicine and Surgery, 2018, 28, 34-37.	1.1	3
12	Measurement of the Retention Time of Different Ophthalmic Formulations with Ultrahigh-Resolution Optical Coherence Tomography. Current Eye Research, 2018, 43, 499-502.	1.5	23
13	Anorectal mucosal melanoma. Oncotarget, 2018, 9, 8785-8800.	1.8	68
14	D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. Clinical and Experimental Gastroenterology, 2018, Volume 11, 373-380.	2.3	18
15	Topical Curcumin Nanocarriers are Neuroprotective in Eye Disease. Scientific Reports, 2018, 8, 11066.	3.3	73
16	Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer. Biomedicines, 2018, 6, 24.	3.2	10
17	Resveratrol in Patients with Minimal Hepatic Encephalopathy. Nutrients, 2018, 10, 329.	4.1	38
18	Progressive Supranuclear Palsy: Neuropsychopathological, Therapeutical and Bioethical Aspects. Current Alzheimer Research, 2018, 15, 959-963.	1.4	5

#	Article	IF	Citations
19	Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. World Journal of Hepatology, 2018, 10, 448-451.	2.0	5
20	Differentially Enhancing Effects of Long-term Treatment with Serrazyme, Boswellia and Pine on Seminal Bacterial Detection in Patients with Chronic Bacterial or Inflammatory Prostatitis, Probably Related to Several Degrees of Bacterial Adherence. Current Clinical Pharmacology, 2018, 13, 183-189.	0.6	1
21	Ultrasound as point of care in management of polytrauma and its complication. Journal of Ultrasound, 2017, 20, 171-177.	1.3	23
22	Topical Coenzyme Q10 demonstrates mitochondrial-mediated neuroprotection in a rodent model of ocular hypertension. Mitochondrion, 2017, 36, 114-123.	3.4	78
23	Tumor lysis syndrome in an extraskeletal osteosarcoma: a case report and review of the literature. Journal of Medical Case Reports, 2017, 11, 79.	0.8	10
24	Job performance in chronic hepatitis C virus patients treated with pegylated interferon- $\hat{l}\pm2b$ plus ribavirin: an observational study. Translational Medicine Communications, 2017, 2, .	1.4	1
25	Change in Coefficient of Fatigability Following Rapid, Repetitive Movement Training in Post-Stroke Spastic Paresis: A Prospective Open-Label Observational Study. Journal of Stroke and Cerebrovascular Diseases, 2017, 26, 2536-2540.	1.6	17
26	Lipoprotein(a) in patients with hepatocellular carcinoma and portal vein thrombosis. Aging Clinical and Experimental Research, 2017, 29, 185-190.	2.9	24
27	Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance. Nutrients, 2017, 9, 897.	4.1	27
28	Reduction of cardiovascular risk in subjects with high lipoprotein (a) levels. Journal of Thoracic Disease, 2017, 9, 2332-2336.	1.4	7
29	The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathologica Communications, 2016, 4, 86.	5.2	81
30	Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry, 2016, 16, 398.	2.6	22
31	Hepatocellular carcinoma and the risk of occupational exposure. World Journal of Hepatology, 2016, 8, 573.	2.0	67
32	Chronic hepatitis C: This and the new era of treatment. World Journal of Hepatology, 2016, 8, 92.	2.0	69
33	Folate status in type 2 diabetic patients with and without retinopathy. Clinical Ophthalmology, 2015, 9, 1437.	1.8	37
34	Effect of a Gluten-Free Diet on Cortical Excitability in Adults with Celiac Disease. PLoS ONE, 2015, 10, e0129218.	2.5	42
35	Microenvironmental Modulation of Decorin and Lumican in Temozolomide-Resistant Glioblastoma and Neuroblastoma Cancer Stem-Like Cells. PLoS ONE, 2015, 10, e0134111.	2.5	44
36	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	1.9	25

#	Article	IF	Citations
37	Clinical update in optic nerve disorders. Expert Review of Ophthalmology, 2015, 10, 145-166.	0.6	O
38	Endozepine-4 levels are increased in hepatic coma. World Journal of Gastroenterology, 2015, 21, 9103.	3.3	11
39	Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. American Journal of Translational Research (discontinued), 2015, 7, 2510-8.	0.0	13
40	Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives. World Journal of Gastroenterology, 2014, 20, 16639.	3.3	113
41	What is changing in indications and treatment of hepatic hemangiomas. A review. Annals of Hepatology, 2014, 13, 327-339.	1.5	137
42	Homocysteine Serum Levels in Diabetic Patients with Non Proliferative, Proliferative and without Retinopathy. BioMed Research International, 2014, 2014, 1-4.	1.9	40
43	Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies. BioMed Research International, 2014, 2014, 1-15.	1.9	66
44	Rare Benign Tumors of the Liver: Still Rare?. Journal of Gastrointestinal Cancer, 2014, 45, 202-217.	1.3	13
45	Low levels of 17-β-oestradiol, oestrone and testosterone correlate with severe evaporative dysfunctional tear syndrome in postmenopausal women: a case–control study. British Journal of Ophthalmology, 2014, 98, 371-376.	3.9	58
46	Excitability of the Motor Cortex in De Novo Patients with Celiac Disease. PLoS ONE, 2014, 9, e102790.	2.5	42
47	Hepatocellular carcinoma markers in the omics era: the glycomic analysis. Hepatobiliary Surgery and Nutrition, 2014, 3, 407-9.	1.5	9
48	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin: Effect on Work Performance. A Randomized Clinical Trial. Hepatitis Monthly, 2014, 14, e11608.	0.2	22
49	What is changing in indications and treatment of hepatic hemangiomas. A review. Annals of Hepatology, 2014, 13, 327-39.	1.5	55
50	Modulation of Chitotriosidase During Macrophage Differentiation. Cell Biochemistry and Biophysics, 2013, 66, 239-247.	1.8	48
51	Evaluation of CHI3L-1 and CHIT-1 Expression in Differentiated and Polarized Macrophages. Inflammation, 2013, 36, 482-492.	3.8	81
52	Evaluation of AMCase and CHIT-1 expression in monocyte macrophages lineage. Molecular and Cellular Biochemistry, 2013, 374, 73-80.	3.1	33
53	TMS follow-up study in patients with vascular cognitive impairment-no dementia. Neuroscience Letters, 2013, 534, 155-159.	2.1	38
54	Metal fume fever. Lancet, The, 2013, 381, 2298.	13.7	7

#	Article	IF	CITATIONS
55	Systemic therapies in hepatocellular carcinoma: present and future. Future Oncology, 2013, 9, 1533-1548.	2.4	42
56	Preserved Transcallosal Inhibition to Transcranial Magnetic Stimulation in Nondemented Elderly Patients with Leukoaraiosis. BioMed Research International, 2013, 2013, 1-5.	1.9	45
57	Carbohydrate 19.9 Antigen Serum Levels in Liver Disease. BioMed Research International, 2013, 2013, 1-6.	1.9	27
58	Lipoprotein(a) in Cardiovascular Diseases. BioMed Research International, 2013, 2013, 1-9.	1.9	59
59	Lipoprotein(a) Serum Levels in Diabetic Patients with Retinopathy. BioMed Research International, 2013, 2013, 1-5.	1.9	23
60	Serum Markers of Intrahepatic Cholangiocarcinoma. Disease Markers, 2013, 34, 219-228.	1.3	64
61	Neurotoxicity of Acrylamide in Exposed Workers. International Journal of Environmental Research and Public Health, 2013, 10, 3843-3854.	2.6	160
62	Skin Cancers in Elderly Patients. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1406-1411.	1.7	15
63	Serum markers of intrahepatic cholangiocarcinoma. Disease Markers, 2013, 34, 219-28.	1.3	42
64	Work Productivity and Activity Impairment in Breast Cancer Patients Treated with Capecitabine. Journal of Cancer Therapy, 2013, 04, 1224-1227.	0.4	3
65	Work Productivity and Activity Impairment in Colorectal Cancer Patients Treated with Capecitabine. Journal of Cancer Therapy, 2013, 04, 1198-1202.	0.4	3
66	Risk of Hepatocellular Carcinoma in Workers Exposed to Chemicals. Hepatitis Monthly, 2012, 12, e5943.	0.2	23
67	Toxic hepatitis in occupational exposure to solvents. World Journal of Gastroenterology, 2012, 18, 2756.	3.3	120
68	Rasburicase for the treatment of tumor lysis in hematological malignancies. Expert Review of Hematology, 2012, 5, 27-38.	2.2	12
69	Hepatic echinococcosis: Clinical and therapeutic aspects. World Journal of Gastroenterology, 2012, 18, 1448.	3.3	253
70	A musician's dystonia. Lancet, The, 2012, 379, 2116.	13.7	11
71	Hepatocellualar Carcinoma Serum Markers. Seminars in Oncology, 2012, 39, 410-433.	2.2	147
72	Immuno-modulatory effects of vitamin D3 in human monocyte and macrophages. Cellular Immunology, 2012, 280, 36-43.	3.0	130

#	Article	IF	Citations
73	Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surgery, 2012, 12, S7.	1.3	32
74	Depression in older breast cancer survivors. BMC Surgery, 2012, 12, S14.	1.3	20
75	Potential role of probiotics on colorectal cancer prevention. BMC Surgery, 2012, 12, S35.	1.3	180
76	Centenarians and supercentenarians: a black swan. Emerging social, medical and surgical problems. BMC Surgery, 2012, 12, S36.	1.3	40
77	Probiotics in the gastrointestinal diseases of the elderly. Journal of Nutrition, Health and Aging, 2012, 16, 402-410.	3.3	65
78	Bifidobacterium longum with Fructo-Oligosaccharides in Patients with Non Alcoholic Steatohepatitis. Digestive Diseases and Sciences, 2012, 57, 545-553.	2.3	369
79	Acetyl-l-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scandinavian Journal of Gastroenterology, 2011, 46, 750-759.	1.5	69
80	Motor cortex excitability in vascular depression. International Journal of Psychophysiology, 2011, 82, 248-253.	1.0	44
81	Enhanced motor cortex facilitation in patients with vascular cognitive impairment-no dementia. Neuroscience Letters, 2011, 503, 171-175.	2.1	43
82	Markers of bile duct tumors. World Journal of Gastrointestinal Oncology, 2011, 3, 49.	2.0	31
83	Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: a randomized and controlled clinical trial. Metabolic Brain Disease, 2011, 26, 281-289.	2.9	49
84	Transcranial magnetic stimulation in Alzheimer's disease: a neurophysiological marker of cortical hyperexcitability. Journal of Neural Transmission, 2011, 118, 587-598.	2.8	74
85	Motor cortex hyperexcitability in subcortical ischemic vascular dementia. Archives of Gerontology and Geriatrics, 2011, 53, e111-e113.	3.0	26
86	A Review of Transcranial Magnetic Stimulation in Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2011, 31, 71-80.	1.5	47
87	Lipoprotein(a) as a potential marker of residual liver function in hepatocellular carcinoma. Indian Journal of Medical and Paediatric Oncology, 2011, 32, 71-75.	0.2	23
88	Serum bone sialoprotein levels and bone metastases. Journal of Cancer Research and Therapeutics, 2011, 7, 115.	0.9	17
89	Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. European Journal of Gastroenterology and Hepatology, 2010, 22, 199-206.	1.6	101
90	Serum Markers of Hepatocellular Carcinoma. Digestive Diseases and Sciences, 2010, 55, 2744-2755.	2.3	166

#	Article	IF	CITATIONS
91	The physiopathology of lipoprotein a. Frontiers in Bioscience - Scholar, 2010, S2, 866-875.	2.1	21
92	Serum markers of cutaneous melanoma. Frontiers in Bioscience - Elite, 2010, E2, 1115-1122.	1.8	16
93	The translational roadmap of the gut models, focusing on gut-on-chip. Open Research Europe, 0, 1, 62.	2.0	1
94	Perspectives on Open Science and Scholarly Publishing: a Survey Study Focusing on Early Career Researchers in Europe. F1000Research, 0, 10, 1306.	1.6	1